MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN

被引：0
|
作者：
Holmberg, C. [1 ]
Aultman, R. [2 ]
Siebert, U. [3 ]
Sabate, E. [4 ]
Gyldmark, M. [2 ]
机构：
[1] F Hoffmann La Roche AB, Stockholm, Sweden
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[4] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73307-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [21] Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer (vol 77, pg 113, 2009)
    Chiara, Silvana
    [J]. ONCOLOGY, 2009, 77 (3-4) : 256 - 256
  • [22] First-line bevacizumab plus infusional 5-FU/irinotecan in metastatic CRC: Initial data from the AVIRI trial
    Sobrero, A.
    Ackland, S.
    Perez Carrion, R.
    Chiara, S.
    Clarke, S.
    Garcia Giron, C.
    Langer, B.
    Zurlo, A.
    Young, S.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 31 - 31
  • [23] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [24] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
    Falcone, Alfredo
    Ricci, Sergio
    Brunetti, Isa
    Pfanner, Elisabetta
    Allegrini, Giacomo
    Barbara, Cecilia
    Crino, Lucio
    Benedetti, Giovanni
    Evangelista, Walter
    Fanchini, Laura
    Cortesi, Enrico
    Picone, Vincenzo
    Vitello, Stefano
    Chiara, Silvana
    Granetto, Cristina
    Porcile, Gianfranco
    Fioretto, Luisa
    Orlandini, Cinzia
    Andreuccetti, Michele
    Masi, Gianluca
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1670 - 1676
  • [25] Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure
    Alkis, N.
    Demirci, U.
    Benekli, M.
    Yilmaz, U.
    Isikdogan, A.
    Sevinc, A.
    Ozdemir, N. Y.
    Koca, D.
    Yetisyigit, T.
    Kaplan, M. A.
    Uncu, D.
    Unek, T.
    Gumus, M.
    [J]. JOURNAL OF BUON, 2011, 16 (01): : 80 - 83
  • [26] PHASE II STUDY OF FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) WITH GONO-FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) PLUS BEVACIZUMAB (BV)
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Ciprotti, M.
    Donati, S.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 136 - 137
  • [27] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [28] A large phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in metastatic CRC:: AVIRI
    Sobrero, A.
    Young, S.
    Balcewicz, M.
    Chiara, S.
    Perez-Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII18 - VII19
  • [29] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [30] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345